- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
EMA Begins Review of Samsung Bioepis' Ranibizumab
The European Medicines Agency (EMA) regulatory review advances a pact between Samsung Bioepis and Biogen announced last year.
The European Medicines Agency has initiated review of a proposed ranibizumab biosimilar (SB11) from Samsung Bioepis. The product candidate references Roche’s Lucentis and would treat retinal vascular disorders, a leading cause of blindness.
Samsung Bioepis developed the product and under a commercialization agreement announced in November 2019, Biogen will handle the marketing of both SB11 and an aflibercept biosimilar (SB15), which is an ophthalmology agent referencing Eylea, a Regeneron Pharmaceuticals/Bayer product. Biogen would manage sales of both products in the United States, Japan, Europe, Canada, and Australia.
“We believe SB11 has the potential to be a meaningful new offering for patients with retinal vascular disorders, and we look forward to continued engagement with the EMA throughout the review process,” Hee Kyung Kim, senior vice president for the Clinical Sciences and Regulatory Affairs Division at Samsung Bioepis, said in a statement.
Ranibizumab is an anti–vascular endothelial growth factor (VEGF) therapy that is used to block the excess development of blood vessels in the eye, which can contribute to the development of disease and tumor formation.
Aflibercept is used to treat wet macular degeneration and metastatic colorectal cancer. It is also an anti-VEGF product.
Samsung Bioepis is based in Incheon, Republic of Korea, and Biogen is in Cambridge, Massachusetts.
Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD
April 3rd 2025The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars
March 19th 2025Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, demonstrating real-world safety of biosimilar-to-biosimilar switching.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
